Argatroban is a synthetic direct reversible thrombin inhibitor API applied dominantly in clinical anticoagulant field and biopharmaceutical research industry. It selectively binds active site of free and clot-bound thrombin to block fibrin generation, platelet aggregation and endogenous coagulation cascade without relying on antithrombin III for activation, differing structurally from heparin series anticoagulants. In formal clinic application, refined raw material is formulated into sterile injection solution for prevention and therapy of deep vein thrombosis and arterial embolism in patients diagnosed with heparin-induced thrombocytopenia (HIT), anaphylactic disorder after heparin administration where conventional heparin cannot be used safely. It also serves emergency anticoagulation during interventional cardiovascular surgeries including percutaneous coronary intervention to avoid intraoperative vascular thrombus formation. For biotech laboratory usage, high-purity grade works as targeted screening reagent for thrombin-related drug development and in-vitro blood coagulation mechanism research to test inhibitor activity of candidate compounds against serine protease thrombin. All finished injectable formulations are strict prescription drugs under global pharmaceutical supervision, with dosage customized per patient coagulation index to prevent excessive bleeding risk.
Argatroban’s core clinical risk originates from over-anticoagulation under improper dosage control, which easily triggers spontaneous bleeding complications such as subcutaneous ecchymosis, gastrointestinal hemorrhage and intracranial bleeding; continuous medication requires regular activated partial thromboplastin time monitoring to adjust infusion speed timely. Mild adverse responses include transient fever, headache and digestive upset while individual hypersensitivity cases presenting skin rash occasionally emerge after intravenous drip administration. Patients with active hemorrhagic diseases, severe hepatic and renal insufficiency are contraindicated for this medicine to avoid aggravated visceral bleeding and drug metabolic accumulation. During raw material production, workshop operators need to equip dust-proof respirators and impermeable latex gloves; long-term repeated powder inhalation irritates nasal and throat mucosa, and direct ocular contact demands abundant running water flushing for over 15 minutes to relieve conjunctival irritation. Unused residual bulk powder belongs to pharmaceutical hazardous waste and must be delivered to certified professional disposal institutions instead of random discharge into sewer or soil. Pregnant women and breastfeeding females only receive this drug when therapeutic benefit overwhelms potential body risk under strict physician evaluation.
Product
